Carboplatin

Name: Carboplatin
Brand: Selleck Chemicals
SKU: S1215
Rating: 5 (62 reviews)

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

62 publications

CAS No. 41575-94-4

Carboplatin (JM-8, CBDCA, NSC 241240) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Selleck's Carboplatin has been cited by 62 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2013, 24(5):617-30

PubMed: 24229709 ( click the link to review the publication )

Eur J Pharmacol, 2021, 895:173887

PubMed: 33482182 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):1975

PubMed: 32332851 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(4):e11177

PubMed: 32115889 ( click the link to review the publication )

Cancer Res, 2020, 80(4):890-900

PubMed: 31857293 ( click the link to review the publication )

Cancer Lett, 2020, 472:59-69

PubMed: 31866467 ( click the link to review the publication )

Sci Signal, 2020, 13(619)

PubMed: 32071169 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):975

PubMed: 33184273 ( click the link to review the publication )

Br J Cancer, 2020, 3

PubMed: 32242101 ( click the link to review the publication )

J Clin Med, 2020, 28;9(4) pii: E924

PubMed: 32231055 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):42

PubMed: 32169072 ( click the link to review the publication )

J Gynecol Oncol, 2020, 31(3):e28

PubMed: 31912682 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Cell Oncol, 2020, 7(6):1805094

PubMed: 33235906 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30647-9

PubMed: 33278498 ( click the link to review the publication )

Neuropathol Appl Neurobiol, 2020, 10.1111/nan.12641

PubMed: 32603552 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )
Oncotarget, 2020, 11(40):3660-3674

PubMed: 33088426 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(19):5925-5936

PubMed: 31300448 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):714

PubMed: 31558709 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

Mol Hum Reprod, 2019, 25(10):601-613

PubMed: 31393565 ( click the link to review the publication )

Biol Res, 2019, 52(1):13

PubMed: 30894224 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Mol Ther, 2018,

PubMed: 29724685 ( click the link to review the publication )

Cancer Lett, 2018, 436:75-86

PubMed: 30120964 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

Oncol Lett, 2018, 16(6):7131-7138

PubMed: 30546448 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Cell Rep, 2017, 19(1):101-113

PubMed: 28380350 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):93

PubMed: 28810913 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28060758 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2017, 8:317-329

PubMed: 28918032 ( click the link to review the publication )
Oncotarget, 2017,

PubMed: 28086243 ( click the link to review the publication )

Sci Rep, 2017, 7:42319

PubMed: 28176879 ( click the link to review the publication )

Nat Commun, 2016, 7:12351

PubMed: 27484502 ( click the link to review the publication )

Nat Commun, 2016, 7:12088

PubMed: 27357444 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-16-0004

PubMed: 27256375 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26047477 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(14):3849-61

PubMed: 24850841 ( click the link to review the publication )

University of South Florida, 2014, /

PubMed: / ( click the link to review the publication )

PLoS One, 2013, 8(9):e72637

PubMed: 24039787 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[6]

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Tca8113/ut	NGDHbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOyMVI26oDLzszN	M4SwU\|czKGh?		M1fvVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
Tca8113/CBP	M3\YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{S3dFIuOjYkgJpOwG0>	M{DvWlczKGh?		MmjlbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NGHCXlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|ExPSd-Mk[xN\|cyODV:L3G+
Tca8113/PYM	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TlZlIuOjYkgJpOwG0>	NIfifYQ4OiCq		NEfHRW1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
SKOV3	NF22VFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nTRlYxKG2pL33s	MUOxMVUh\A>?		NF7mfmxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTD0bY1mKGSncHXu[IVvfGy7	Ml\2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewOFMoRjJ4MUO3NFQ{RC:jPh?=
SKOV3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTxNE01KM7:Zz;tcC=>	MoLQNlQwPDhxN{KgbC=>		NY\1Wm1HcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	NEnERmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3	MlvQRZBweHSxc3nzJGF{e2G7	NFft[nEzKM7:Zz;tcC=>	NUTj[4g2PDhiaB?=		MlTObY5lfWOnczDhdI9xfG:\|aYO=	NYDvVXhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNlUzPzNpPkK2NVI2Ojd\|PD;hQi=>
OSA	M4m2NmNtd26xZ3XubYMhSXO\|YYm=	M2\zd\|IvPS93IN88US=>			NYr1eXJoemW\|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?=	M{XGdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUGwOlIxLz5{NkGxNFYzODxxYU6=
A549	M4TMR2Z2[3Srb36gRZN{[Xl?	NVnKTJN6OC9{NT:1NEDPxE1?	NV7GWVhOOjRiaB?=		Mlvz[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	NWrNW2VrTnWldHnvckBCe3OjeR?=	NGX1c3UxNzJ3L{WwJO69VQ>?	MXOyOEBp		NHHWcFlld3ewcnXneYxifGW\|IH3pVk0zODViZYjwdoV{e2mxbtMg	MnvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
A549	MVnGeYN1cW:wIFHzd4F6	Ml:1NE8zPS93MDFOwG0>	MYqyOEBp		MWf1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
H1975	MluxSpVkfGmxbjDBd5NigQ>?	MXuwM\|I2NzVyIN88US=>	MYmyOEBp		NWDZbpU{fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w	NH;UfI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
A549	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPESGJbOjVizszN	NHPDXFEzPCCq		M1LzcolvcGmkaYTzJINmdGxiZ4Lve5Rp	MnrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
H1975	NHHSTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfOOmYzPSEQvF2=	NHXSc5ozPCCq		MlPkbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	Mn7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
MDA-MB-231	M4rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mki5NE0zOjBizsznM41t	NHizVok4OiCq		NWn2eIFTUUN3MNMgQUA5PiEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|N{[5NUc,OjV6M{e2PVE9N2F-
T47D	M1O0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXxOHdNOC1{MkCg{txoN22u	M3P1T\|czKGh?		M{i4S2lEPTEEoE2gOFgvQSEQvF2=	NG\UT4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizO\|Y6OSd-MkW4N\|c3QTF:L3G+
LCTCC	NUjzO2c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTNwOPMAjeK2VQ>?	NFf4XJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N\|E3Pyd-MkW3O\|MyPjd:L3G+
MCTCC	NFvvb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTJwOPMAjeK2VQ>?	NFfOWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N\|E3Pyd-MkW3O\|MyPjd:L3G+
MegTCC	NFPz[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvubmtKSzVyPUSuNgKBkcL3TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC	NVfTd3dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy2c4hKSzVyPUWuOwKBkcL3TR?=	M4naeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ezNVY4Lz5{NUe3N\|E3PzxxYU6=
MCF7	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDJ[4QzOCEQvF2=	NX;5OZF2PzJiaB?=		MULpcoR2[2W\|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=>	NXTY[nJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlkxOjVpPkK1O\|Y6ODJ3PD;hQi=>
A-549	M3WyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH1NE42KM7:TR?=	Mm\XNlQhcA>?	NH\iclVFVVORwrC=	MnSybY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?=	NYr5dXBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O\|U2PjlyPD;hQi=>
A-549	NYnNb2t5SXCxcITvd4l{KEG\|c3H5	MV[wMlUh\|ryP	M2fUNVQ5KGh?	M{LxTmROW00EoB?=	M3XzV5Npd3e\|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25?	NHHVbmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1OVY6OCd-MkW3OVU3QTB:L3G+
A-549	MYDGeYN1cW:wIFHzd4F6	M1zMTlAvPSEQvF2=	M16xWFQ5KGh?	M3zBN2ROW00EoB?=	NW[xVYlPe2ixd4OgZYJmenKjboSgcYlkem:2dXL1cIUh\Gm\|coXweIlwdg>?	NUS0VnNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVU3QTBpPkK1O\|U2PjlyPD;hQi=>
A-549	M{HycmZ2[3Srb36gRZN{[Xl?	NXvMdnFFOC53IN88US=>	MnnyOFghcA>?	NIDTR5VFVVORwrC=	NEHrOZNqdmirYnn0d{Bw\iClZXzsJI1q\3KjdHnvcuKh	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
RMG-1	M2\BRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHiXZpKSzVyPUK4MlghyrFiMz62JI1oN0x?	NVmxVIFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlY6OTNpPkK1O\|I3QTF\|PD;hQi=>
FN-RMG-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPqTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{NkmxN{c,OjV5Mk[5NVM9N2F-
RMG-1-hFUT	NYTUbGhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvZc21KSzVyPUW4MlEhyrFiMj60JI1oN0x?	MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
FN-RMG-1-hFUT	M1TDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTFzOD64JOKyKDF\|LkigcYcwVA>?	M1X5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K2PVE{Lz5{NUeyOlkyOzxxYU6=
CHP-134	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{j3[\|Eh\|ryP		MUjEUXNQyqB?	NEHPS\|BqdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N\|A{PzF?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
IMR-32	NGLXSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrkNUDPxE1?		MYHEUXNQyqB?	NUK0foducW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
CHP-134	NGPtb5RHfWO2aX;uJGF{e2G7	M1joe\|ExKM7:TdMg		Mn;WSG1UV8Li	Moe1bY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO\|E>	M2HIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32	MkPDSpVkfGmxbjDBd5NigQ>?	MmXzNVAh\|ryPwrC=		NEnQXIhFVVORwrC=	MWXpcoR2[2W\|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh\|MEO3NS=>	M1zuOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
A549	NV3U[4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn1PZExNjJvNECwNEDPxE1?	MknYO\|IhcA>?		NWfpOJBvUUN3ME2xNlYhyrFiNT6wJO69VQ>?	M2jBbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
A549/CDDP	NXu4XY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXORZkxNjJvNECwNEDPxE1?	MWO3NkBp		NInGfWlKSzVyPUK0NOKhyrIEoES1Mlch\|ryP	NUHCN2JERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlUzPDNpPkK1OlI2OjR\|PD;hQi=>
H460	M1XCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFPCbWYzPCCq	M1XwT2ROW09?	MlLlTWM2OD15Lkmg{txO	Mm\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
H460	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr1dHNwPy57IN88US=>	MXiyOEBp	Mk\1SG1UVw>?	Mn3Gd4hwf3NiYTDyZYRqd3OnboPpeIl7cW6pIHXm[oVkfCC2bzDYMZJigXN?	MkXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUm5PVUoRjJ3NUm5PVk2RC:jPh?=
NRK-52E	NYCyfG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1Kz[VczyqCqwrC=		NWnpT3FjUUN3ME2xNFAhyrFiMUKuPUDPxE1?	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
RGE	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\TO\|LDqGkEoB?=		M4HFNGlEPTB;MkKgxtEhPy52IN88US=>	MkTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
NRK-52E	NITWU\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NELGT5g4OsLiaNMg		MVLJR\|gxRTF5OTFCtUA6NjVizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
RGE	NFTMdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{jqPFczyqCqwrC=		Ml7UTWM5OD14MzFCtUA4NjRizszN	M3OwR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[1OlA{Lz5{NUW2OVYxOzxxYU6=
SK-OV-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnTKO\|IhcA>?		Mo[yTWM2OD1zMESuPEDPxE1?	NXXKSJdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
ES-2	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1PHflczKGh?		NH7UNXFKSzVyPUG0MlYh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
OVCAR-8	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkLzO\|IhcA>?		MVTJR\|UxRTl4LkCg{txO	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
3AO	NYHSXpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmTOO\|IhcA>?		M2G0d2lEPTB;NkOuOEDPxE1?	NFXjNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780	NYHkZXAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1PQZ\|czKGh?		NHvpTpNKSzVyPUG0OU44KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
SW626	NFHPPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHnSfGI4OiCq		MWfJR\|UxRTl5LkCg{txO	M2LYZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3Dd2s4OiCq		NEj3U5BKSzVyPUOyMlYh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
A549	M1zSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF3MT61OkDDuSB3Mz6wOkDPxE1?	NWnueGNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
4T1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHETWM2OD16ND62NkDDuSB\|MD6wOUDPxE1MIN88US=>	M3nMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
BALB/3T3	NWjleo1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojOTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>?	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
B16	NGnDVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfLRYhKSzVyPU[0MlMxKMLzIE[uPFEh\|ryP	NVrCeo8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
DU 145	NV\4d2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>?	M4L5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
FaDu	NY\tSHAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HCV-29T	NX25fGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\NT2lEPTB;NEiuOVchyrFiMkKuOFkh\|ryP	MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
HL-60	NXO2UJJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jlTmlEPTB;MUGuNVAhyrFiND60O{DPxE1?	NInT[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q3OSd-MkWyO\|c1PjF:L3G+
HT-29	NWe5UnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\6eWlEPTB;OEmuNVYhyrFiMUiuPFYh\|ryP	M4XKbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
H146	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfydo5xUUN3ME20PU43yrFzMz6xJO69VQ>?	M1e0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H187	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnj5TWM2OD1zMj63xtEzNjdizszN	NIj6OmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H128	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFyNj60xtE6NjZizszN	M1SxVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
H69	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHleHBKSzVyPUe2MlnDuTJ5Lkig{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209	M3\pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\lU493UUN3ME2yOVgvOcLzOUmuPEDPxE1?	NGKxO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS153	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTieG5iUUN3ME21O{45yrF7LkKg{txO	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H526	M2fJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjmTWM2OD15LkNCtVEvPyEQvF2=	M{\PR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
DMS114	NVjoeY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7aNXN7UUN3ME24OU45yrFzMj64JO69VQ>?	MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
DMS53	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnr4TWM2OD1zNE[uNuKyOzZwNDFOwG0>	M3j1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUK0NlgzLz5{NUGyOFI5OjxxYU6=
HeLa	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGm5OWM2NThyIN88US=>			MnrqbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N\|YxRC:jPh?=
MCF-7	MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvkOU05OCEQvF2=			M1TqSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	Ml7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N\|YxRC:jPh?=
MDA-MB-231	NGTtRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnDcIY2PS16MDFOwG0>			MXXpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N\|YxRC:jPh?=
CaOV3	NHvsc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2DUbFczKGh?		NILTc5hKSzVyPUi2MlEh\|ryP	M{L5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-3	M333Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXPUXM4OiCq		MkS3TWM2OD1zN{muOUDPxE1?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-5	NGTqO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DBNVczKGh?		Mle0TWM2OD15NT63JO69VQ>?	Mn3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
SKOV-3	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3GzdFczKGh?		NUn5ZmhHUUN3ME21NFQh\|ryP	NYrjb5VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlg5PDlpPkK1NFY5QDR7PD;hQi=>
OVCAR-4	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV;2b2s2PzJiaB?=		MYXJR\|UxRTJ7MD62JO69VQ>?	NF74Olg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
OVCAR-8	M1nVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp		NXLSZllWUUN3ME22PVAvOiEQvF2=	NFXtcYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2PFg1QSd-MkWwOlg5PDl:L3G+
MA148	M1vZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHHKT3kzPCCq		NHHLUpJKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw>	M4SwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549	M1v1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXeyOEBp		M4PMRWlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw>	M{DxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1Xh[lI1KGh?		M3PYTWlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw>	M17oVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES	NH3GXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\nS3RZOjRiaB?=		MnKzTWM2OD1zN{WzMlDjiIoEsfMAjVQvPCEQvHevcYw>	NF7GcWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
MA148	NXnYV5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXPLNHZwPDhiaB?=		NH;PUXVKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw>	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549	NF\USoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWPqOIFWPDhiaB?=		MUnJR\|UxRTFzOD6w5qCKyrIkgJmxMlIh\|rypL33s	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231	Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUS0PEBp		MULJR\|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=>	NFuwdVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
NCI-ADR/RES	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF3Tc4I1QCCq		MkDwTWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=>	NFzmT\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
MA148	M3\Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEDMbFQ4OiCq		M{TvOGlEPTB;MUOuO-KBkcLz4pEJNU4zKM7:Zz;tcC=>	NEDN[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
A549	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmXTO\|IhcA>?		NGTmRnBKSzVyPU[0MlPjiIoEsfMAjVEvOSEQvHevcYw>	MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
MDA-MB-231	NGXiS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYW3NkBp		M2XHdGlEPTB;OUmuOgKBkcLz4pEJNU4yKM7:Zz;tcC=>	MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES	NHzOXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{jBdVczKGh?		NWLzVG1zUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t	NGG4Z3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizNVA6OSd-MkS4N\|ExQTF:L3G+
A549	NIfyUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnLVO\|IhcA>?	MY\EUXNQ	NYn3bXZSUUN3ME2xOVIvPDB7IN88US=>	NXXsV4dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlE{OjNpPkK0O\|IyOzJ\|PD;hQi=>
NCI-H157	NV;qdVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnT4O\|IhcA>?	MVvEUXNQ	Mn7WTWM2OD16OT65O\|ch\|ryP	M1fzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KxN\|I{Lz5{NEeyNVMzOzxxYU6=
PC9	NFmzO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYnTe\|VHPzJiaB?=		NInnc4dISzVyPUexMlbDuTlwNTFCuW0>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549	M3ywfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUnudYRRPzJiaB?=		M3fCbWdEPTB;MUO2xtE{OS54INM1UeKh	NWG4WlBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NVg5ODlpPkK0OlE5QDB7PD;hQi=>
PC9	NFHPfIFCeG:ydH;zbZMhSXO\|YYm=	NV;l[mVHOTByINM1US=>	MUm3NkBp		NEjlTVlqdmS3Y3XzJIFxd3C2b4Ppdy=>	NITnS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
A549	MWfBdI9xfG:\|aYOgRZN{[Xl?	NYfqWlV4OTByINM1US=>	NUnGc2FiPzJiaB?=		NFTsfZpqdmS3Y3XzJIFxd3C2b4Ppdy=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549	NUSxbldjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[yOEBp		NYe5VY8{UUNzME2xMlQ4PiCwTR?=	M2LDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{m2OFM4Lz5{NEO5OlQ{PzxxYU6=
H1299	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLOUpgzPCCq		M3;3fWlEOTB;MD60OFMhdk1?	NHHTb4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5OlQ{Pyd-MkSzPVY1Ozd:L3G+
HCC15	NEHuWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NG\kSFczPCCq		MV;JR\|ExRTBwM{S2JI5O	NYXIO\|JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
H157	M2W1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTnNlQhcA>?		MWfJR\|ExRTBwOEGgcm0>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR\|OU[0N\|c9N2F-
A2780	NWi5b4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\CTWM2OD1zND6w5qCKyrIkgJmxMlQh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-
A2780cisR	NXPLfmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTR6LkpihKnDueLCiUOuPUDPxE1?	NFWxUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKwPVY6Oyd-MkSyNFk3QTN:L3G+
A2780ZD0473R	M1nRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fqemlEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?=	M17yPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
SKOV-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlP2TWM2OD12Mz605qCKyrIkgJmzMlkh\|ryP	M33LXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChK-2 / Chk-2 ; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p38 / p38 / Cleaved PARP / PARP ; PubMed: 30049957 Int J Mol Sci A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄	30049957
Immunofluorescence	γH2AX ; PubMed: 24348048 Onco Targets Ther Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ	24348048
Growth inhibition assay	Cell viability ; PubMed: 24348048 Onco Targets Ther SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay.	24348048

In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: A2780, SKOV3, IGROV-1 and HX62
Concentrations: 0-200 μM
Incubation Time: 72 hours
Method:
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
Administration: Administered via i.p.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	14 mg/mL warmed (37.71 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Carboplatin SDF

Molecular Weight	371.25
Formula	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4
Storage	2 years 4°C(in the dark) powder 1 week 4°C(in the dark) in solvent
Synonyms	JM-8, CBDCA, NSC 241240
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04606914	Not yet recruiting	Drug: mirvetuximab soravtansine (MIRV; IMGN853)	Ovarian Cancer\|Fallopian Tube\|Primary Peritoneal Cancer	University of Alabama at Birmingham	March 31 2021	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?
Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Choose Your Country or Region

By Signaling Pathways

By product type

Carboplatin